X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas Piramal: Riding high - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 15, 2004

    Nicholas Piramal: Riding high

    Nicholas Piramal is one of the leading domestic pharma companies with strong focus on the domestic market. The company has shown a consistent growth performance in the last few years despite the slowdown in the domestic pharma industry. One thing that makes this growth commendable is that unlike other domestic pharma companies, Nicholas Piramal has huge exposure to the extent of 90% of the company's net sales, in the domestic pharma industry.

    Looking at the historical performance, the company has been involved in several leveraged buyouts. FY02 and FY03 were significant years in terms of topline growth, when the company acquired the likes of Rhone-Poulenc India, Boots –Piramal and Allergan India. The company has over the years adopted an inorganic growth strategy. To put things in perspective, at a time, it has as many as 13 subsidiaries. But it has taken a cue from this and has hived -off most of its unrelated businesses (only two subsidiaries now). The company has managed to maintain growth in last two years despite the slowdown in the domestic pharma industry.

    Looking at its operations in the domestic markets, the company has a strong presence in the cardiovascular and respiratory segments (30% of revenues). It must be noted that cardiovascular segment has been the fastest growing in the domestic pharma market (16.9% in 2003). The company's high exposure towards the life style segment makes it an attractive growth story. Also, it has a very low DPCO coverage (12% of total revenues) which gives it the pricing power.

    At the same time, Nicholas Piramal, with a debt to equity ratio of 1:1, is highly leveraged on a relative basis. This strategy can do wonders in good times, but can be disastrous in bad times. But we expect the leverage to decline in the future. The management has also given indication of concentrated inorganic growth strategy in the future.

    The company is also been into R&D activity and has acquired R&D facilities of Hoechst Marrion Roussel Ltd's research center two years back. This facility gives Nicholas an exposure to the established facilities in the new drug research program. It is in the process of establishing a new R&D facility, which will start operations in FY05. The main focus of the company will be in the field of cardiovascular, diabetology, oncology and anti-infective segment.

    On the export front, the company has adopted a slightly different business model wherein it is likely to focus on contract manufacturing and contract research. It has established a new facility for contract manufacturing and the first shipment is expected in the later half of FY05 to AMO Corporation, US.

    At Rs 780, the stock is trading at a P/E of 15x FY05E earnings. Considering its strong presence in the domestic markets, growth prospects look promising. But on the flip side, the high leverage and the lack of focus on the business in past years increases the risk profile of the stock significantly.

     

     

    Equitymaster requests your view! Post a comment on "Nicholas Piramal: Riding high". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    PIRAMAL ENTERPRISES SHARE PRICE


    Aug 16, 2017 (Close)

    TRACK PIRAMAL ENTERPRISES

    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON PIRAMAL ENTERPRISES

    PIRAMAL ENTERPRISES 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE PIRAMAL ENTERPRISES WITH

    MARKET STATS